Key result
Statin plus evolocumab therapy significantly reduced the risk of rehospitalization for unstable angina at 12 months compared to statin monotherapy in STEMI patients with non-infarct-related artery disease (OR 0.350).
Why the study?
The effects of combining evolocumab and statin on clinical outcomes and coronary artery physiological function in STEMI patients with non-infarct-related artery disease remain unclear.
Does evolocumab added to statin therapy improve coronary physiological function and reduce rehospitalization for unstable angina in STEMI patients with non-infarct-related artery disease?
Cohort (n=355)
No
Does evolocumab added to statin therapy improve coronary physiological function and reduce rehospitalization for unstable angina in STEMI patients with non-infarct-related artery disease?
Answers are grounded in this paper and cite their sources.
Adding evolocumab to statin therapy in STEMI patients with non-infarct-related artery disease improves coronary physiological function and significantly reduces the 12-month risk of rehospitalization for unstable angina.
Purpose: The effects of combing evolocumab and statin on the clinical outcome and physiological function of coronary arteries in STEMI patients with non-infarct-related artery (NIRA) disease are still unclear. Methods: 355 STEMI patients with NIRA were enrolled in this study, who underwent combined anatomical and physiological assessments at baseline and after 12 months of treatment with statin monotherapy or statin plus evolocumab. Plaque composition and functional ischemia were determined via using the quantitative coronary angiography (QCA) and quantitative flow ratio (QFR). Results: Diameter stenosis and lesion length were significantly lower in the group undergoing statin plus evolocumab. While the group exhibited significantly higher minimum lumen diameter (MLD), and QFR values. Statin plus evolocumab (OR=0.350) and plaque lesion length (OR=1.223) were independently associated with rehospitalization for unstable angina (UA) within 12 months. Conclusion: Evolocumab combined with statin therapy can significantly improve the anatomical and physiological function of the coronary arteries and downregulate the re-hospitalization rate due to UA in STEMI patients with NIRA.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted a cohort in ST-Elevation Myocardial Infarction (STEMI) with Non-Infarct-Related Artery (NIRA) disease (n=355). Statin plus evolocumab vs. Statin monotherapy (rosuvastatin 20 mg once a day) was evaluated on Rehospitalization for unstable angina (UA) at 12 months (OR 0.350, 95% CI 0.149-0.824, p=0.016). Statin plus evolocumab therapy significantly reduced the risk of rehospitalization for unstable angina at 12 months compared to statin monotherapy in STEMI patients with non-infarct-related artery disease (OR 0.350).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: